交易 Arcutis Biotherapeutics, Inc. - ARQT 差價合約

交易條件

• 類型該金融市場可進行差價合約交易。了解更多：差價合約: 差價合約
• 點差: 0.1
• 長倉隔夜倉息調整長倉隔夜倉息調整保證金。您的投資$1,000.00隔夜倉息來自頭寸全值的費用-0.022207 %(-$0.44)使用杠杆的交易規模（大約值）$2,000.00來自杠杆的資金 - 美元（大約值）$1,000.00前往平台: -0.02221%
• 短倉隔夜倉息調整短倉隔夜倉息調整保證金。您的投資$1,000.00隔夜倉息來自頭寸全值的費用-0.000015 %(-$0.00)使用杠杆的交易規模（大約值）$2,000.00來自杠杆的資金 - 美元（大約值）$1,000.00前往平台: -0.00002%
• 隔夜倉息調整時間: 21:00 (UTC)
• 貨幣: USD
• 最低成交量: 1
• 保證金: 50.00%
• 證券交易所: United States of America
• 交易佣金: 0%
• 保證止損溢價保證止損 (GSL) 費用僅在 GSL 被觸發時收取。更多詳情請參閱我們網站的「服務費用」 頁面。: 1%

• 保證金。您的投資: $1,000.00
• 隔夜倉息來自頭寸全值的費用: -0.022207 %
  (-$0.44)

• 保證金。您的投資: $1,000.00
• 隔夜倉息來自頭寸全值的費用: -0.000015 %
  (-$0.00)

主要統計數據

• 前收盤價: 26.69
• 開倉: 27.21
• 1 年變化: 46.53%
• 日區間: 26.37 - 27.23

交易 Arcutis Biotherapeutics, Inc. - ARQT

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.